Article
The PNPLA3 rs738409 variant can increase the risk of liver toxicity in multiple sclerosis patients treated with beta-interferon.
Clinical neurology and neurosurgery - 1 Oct 2020
Capone Fioravante, De Vincentis Antonio, Ferraro Elisabetta, Rossi Mariagrazia, Motolese Francesco, Picardi Antonio, Giannetti Barbara, Di Battista Giancarlo, Vespasiani-Gentilucci Umberto, Di Lazzaro Vincenzo
Abstract excerpt
BACKGROUND: Liver toxicity can limit the use of interferon-beta (IFNβ), a well-established treatment for multiple sclerosis (MS). Unfortunately, known risk-factors for IFNβ-associated liver toxicity are few and of limited clinical utility. Susceptibility to drug-induced toxicity is influenced by genetic factors affecting hepatic lipid metabolism and drug-metabolizing activity. METHODS: We designed a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.